NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
Clinical Trials
3 trialsNCT01659151 2026-02-20
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01754376 2017-04-12
Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma
Massachusetts General Hospital
Phase 2 Terminated